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Synaptic vesicle protein 2A (SV2A) is an integral membrane protein necessary for the
proper function of the central nervous system and is associated to the physiopathology
of epilepsy. SV2A is the molecular target of the anti-epileptic drug levetiracetam and its
racetam analogs. The racetam binding site in SV2A and the non-covalent interactions
between racetams and SV2A are currently unknown; therefore, an in silico study was
performed to explore these issues. Since SV2A has not been structurally characterized
with X-ray crystallography or nuclear magnetic resonance, a three-dimensional (3D)
model was built. The model was refined by performing a molecular dynamics simulation
(MDS) and the interactions of SV2A with the racetams were determined by docking
studies. A reliable 3D model of SV2A was obtained; it reached structural equilibrium
during the last 15 ns of the MDS (50 ns) with remaining structural motions in the
N-terminus and long cytoplasmic loop. The docking studies revealed that hydrophobic
interactions and hydrogen bonds participate importantly in ligand recognition within the
binding site. Residues T456, S665, W666, D670 and L689 were important for racetam
binding within the trans-membrane hydrophilic core of SV2A. Identifying the racetam
binding site within SV2A should facilitate the synthesis of suitable radio-ligands to study
treatment response and possibly epilepsy progression.
Keywords: SV2A, epilepsy, levetiracetam, brivaracetam, seletracetam
Introduction
Epilepsy is the most common chronic brain disorder that aﬀects people of all ages. More than
50 million people worldwide have epilepsy (WHO, 2014). It is characterized by recurrent seizures,
Abbreviations: AM1, Austin Model 1; BRIV, brivaracetam; CNS, central nervous system; H-bonds, hydrogen bonds; G,
free energy; LEV, levetiracetam; MFS, mayor facilitator family; MDS, molecular dynamics simulation; OPLS-AA, optimized
potentials for liquid simulations all atoms; PET, positron emission tomography; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine; Rg, radius of gyration; RMSD, root mean square deviation; RMSF, root mean square ﬂuctuations;
SAS, solvent accessible surface area; SD, standard deviation; SEL, seletracetam; SV2A, synaptic vesicle protein 2A; 3D,
three-dimensional; TM, trans-membrane; Uniprot, universal protein resource; VMD, visual molecular dynamics.
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which may vary from a brief lapse of attention or muscle jerks,
to severe and prolonged convulsions (WHO, 2014). In most
patients with epilepsy, seizures respond to available medica-
tions. However, a signiﬁcant number of patients -especially in
the setting of medical-intractable epilepsies- may experience dif-
ferent degrees of memory or cognitive impairment, behavioral
abnormalities or psychiatric symptoms, which limit their daily
functioning. As a result, in many patients, epilepsy may resem-
ble a neurodegenerative disease (Ono and Galanopoulou, 2012).
Epileptic seizures and/or epileptogenesis may functionally alter
brain regions involved in cognitive processing, contributing to
the progressive nature of epilepsy; additionally neurodegenera-
tive cellular mechanisms may also participate. To cure epilepsy,
both epileptogenesis and the associated neuro-degeneration have
to be stopped and, if possible, reversed. This will require early
detection through biomarkers that can reliably predict disease
progression (Ono and Galanopoulou, 2012).
Synaptic vesicle protein 2A is an integral membrane pro-
tein present on all synaptic vesicles, being nearly ubiquitous in
the CNS (Lynch et al., 2004). The existing evidence suggests
that SV2A is critical for the proper function of the CNS. It
regulates vesicle exocytosis by modulating the concentration of
pre-synaptic calcium (Janz et al., 1999; Chang and Sudhof, 2009;
Wan et al., 2010); maybe by binding to synaptotagmin 1 (Schivell
et al., 1996, 2005; Yao et al., 2010), a calcium sensor protein
implicated in synaptic vesicle exocytosis. In addition, it has been
proposed that SV2A may control the release of neurotransmit-
ters as a gel matrix or could transport ions, such as chloride or
calcium (Bajjalieh et al., 1994; Janz et al., 1999; Reigada et al.,
2003; Mendoza-Torreblanca et al., 2013). The SV2A protein has
been associated to the physiopathology of epilepsy; newborn
mice lacking SV2A experience severe seizures and die within
3 weeks, suggesting multiple neural alterations (Crowder et al.,
1999; Janz et al., 1999). Moreover, SV2A protein expression
is signiﬁcantly reduced in brain tissue obtained from epilep-
tic patients and in rats during epileptogenesis, suggesting that
decreased SV2A contributes to the progression of epilepsy (Feng
et al., 2009; Toering et al., 2009; van Vliet et al., 2009). SV2A
is the molecular target of the second-generation antiepileptic
drug LEV and its structural analogs BRIV, SEL and UCB-30889
(Gillard et al., 2003; Lynch et al., 2004; Frycia et al., 2010).
Although LEV may acutely modulate ion channels and other tar-
gets; chronically, LEV may lead to decreased transmitter release
predominantly by binding to SV2A (Surges et al., 2008; Crepeau
and Treiman, 2010; Lyseng-Williamson, 2011; Deshpande and
Delorenzo, 2014).
Knowing the in vivo expression pattern of SV2A in epilepsy
patients may be essential for evaluating increased epileptogenic-
ity and thus disease progression (van Vliet et al., 2009). Moreover,
SV2A expression could also be useful as a biomarker for treat-
ment response (de Groot et al., 2011). For this purpose, sensitive
neuroimaging methods such as PET may enhance our ability to
detect SV2A expression (Ono and Galanopoulou, 2012). Because
PET requires the use of a radio-ligand to label the protein tar-
get, as a ﬁrst approximation to synthesize a radio-ligand with a
high aﬃnity and speciﬁcity, we investigated the speciﬁc binding
site(s) for racetams in SV2A and the residues involved in their
interaction. Therefore, an in silico study was performed to iden-
tify the binding site for LEV and other racetams within SV2A.
Since SV2A has not been structurally characterized with X-ray
crystallography or nuclear magnetic resonance, it was necessary
to generate and validate a 3D model of this protein. This model
was reﬁned by a MDS and docking studies were performed to
decipher the interactions between the racetams and SV2A.
Materials and Methods
SV2A modeling
The SV2A protein sequence was retrieved from the National
Center for Biotechnology Information (NP_476558.2) and
UniProt (Q02563). There was no diﬀerence between these
databases; the protein sequence was thus used as an input for
the I-Tasser server (Roy et al., 2010); which provided a clus-
ter of ﬁve 3D models for this protein. The Rampage server
was used to obtain the Ramachandran plot, which shows the
ϕ and ψ torsion angles for all protein residues. Additionally,
the CPHmodels-3.2 and 3D-JIGSAWv3.0 servers were used to
conﬁrm the reproducibility of the SV2A 3D model provided by
I-Tasser.
System Preparation for Molecular Dynamics
Simulation
The model of the SV2A protein was inserted into a pre-
equilibrated membrane consisting of POPC molecules. The
resulting systemwas then placed in a hexagonal prism shaped box
with its symmetry axis, which was perpendicular to the plane of
the bilayer membrane, in the z direction. The system was then
solvated using simple point charge model water molecules. The
geometry and size of the simulation box were carefully selected
to reduce to a minimum the number of water molecules and
thus decrease the computation time. In order to remove solvent
molecules accidentally introduced in the hydrophobic region of
the lipid bilayer, 19 Na+ ions were added to neutralize the whole
system.
The simulation box contained one molecule of SV2A, 342
POPC lipids, 47,671 water molecules and 19 ions, resulting in
a total of 172,298 atoms. The OPLS-AA force ﬁeld was used, it
has been used to simulate and describe several TM proteins with
good results (Tieleman et al., 2006). The simulation was done by
applying the half-ε double-pair list method to ensure compatibil-
ity between the Berger united atom parameters, used for lipids
(Lindahl and Edholm, 2000; Chakrabarti et al., 2010), with the
OPLS-AA force ﬁeld employed for protein and ions (Jorgensen
et al., 1996; Kaminski et al., 2001).
Molecular Dynamics Simulation
The system in its entirety was minimized for 500 steps using the
steepest descent optimization algorithm prior to generating the
MDS trajectory. Solvent–protein and lipid–protein contacts were
optimized by a simulation lasting 5 ns, with harmonic constraints
in the heavy atoms of the protein (all, except for hydrogen). The
force constants of these positional restraints were sequentially
reduced. Afterward, an unrestrained trajectory lasting 50 ns was
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generated. The simulation was performed using a 2 fs time step.
The pressure was set at 1 bar using a semi-isotropic Parrinello and
Rahman (1981) barostat (Nosé and Klein, 1983) to allow inde-
pendent modiﬁcation of the box dimensions in the XY plane and
in the Z dimension. The temperature was kept constant at 310 K
by a Nosé (1984) and Hoover (1985) thermostat. The linear con-
straint solver algorithm was employed to remove bond vibrations
(Hess et al., 1997). The particle mesh Ewald method (Darden
et al., 1993; Essmann et al., 1995) coupled to periodic boundary
conditions was used to simulate long-range electrostatic interac-
tions using a direct space cutoﬀ of 1.2 nm and a grid spacing
of 0.15 nm. Because periodic boundary conditions can produce
periodic artifacts, especially if combined with Ewald methods
(Essmann et al., 1995), the minimum distance between protein
molecules in adjacent boxes was calculated as a function of time.
The simulation box size was adequate for the system, based on
the cutoﬀ used for electrostatic and short range contributions to
the potential function. The van derWaals interactions were com-
puted using periodic boundary conditions coupled to a spherical
cutoﬀ of 1.2 nm. TheMDSwas performed usingGROMACS4.6.1
(Hess et al., 2008). Additionally, a replicate MDS was carried out
in order to conﬁrm the results of the ﬁrst MDS.
FIGURE 1 | 3D SV2A model. The I-Tasser server yielded a model of SV2A
with 742 amino acids distributed in 12 TM domains consisting of α-helices, an
undefined intra-luminal domain and two cytoplasmic domains: a relatively
large N-terminus with a synaptotagmin 1 binding site (arrow) plus an ATP
binding motif (arrow head) and a large loop between TM domains 6–7 with
another ATP binding motif (two arrows heads).
Docking Studies
Docking and MDS simulations were combined by screening dif-
ferent SV2A conformers. LEV, BRIV, SEL and UCB-30889 were
the selected racetam ligands. The criteria to include these lig-
ands were as follows: LEV speciﬁcally binds to SV2A (Lynch
et al., 2004) and is the lead anti-convulsive racetam. BRIV,
SEL and UCB-30889 also bind to SV2A, but with higher
aﬃnity than LEV (Gillard et al., 2003, 2011; Matagne et al.,
2009). BRIV and SEL have been the two leading candidates
to replace LEV, since they were more potent and eﬀective in
animals model studies (Kaminski et al., 2012). Finally, UCB-
30889 has been extensively used to characterize the binding
properties of SV2A (Gillard et al., 2003; Lambeng et al., 2005;
Shi et al., 2011). Interactions between the racetam ligands and
nine SV2A conformers corresponding to every 2 ns during the
last 16 ns of the MDS trajectory (when the system reached
equilibrium) were simulated. In order to obtain the minimum
energy conformation for each ligand structure, they were pre-
optimized with AM1 (a semi-empirical method) and then opti-
mized using the B3LYP/6-31G(d) basis set, both implemented
in Gaussian 03 (Frisch et al., 1998). Dockings were performed
using AutoDock 4.0.1 and AutoDock Tools 1.5.6 (Morris et al.,
2008).
Before starting the docking simulations, hydrogen atoms
were added to the polar atoms (considering a 7.4 pH value)
and the Kollman charges were assigned for all atoms in the
receptor. All rotating bonds, torsional degrees of freedom,
atomic partial charges and non-polar hydrogens of the lig-
ands were assigned. Then the ligands were docked onto the
SV2A protein using a 70 Å × 70 Å × 70 Å grid box
which covered all putative residues involved in racetam recog-
nition according to the literature (Shi et al., 2011). A grid
spacing of 0.375 Å was used under the hybrid Lamarckian
Genetic Algorithm with an initial population of 100 ran-
domly placed individuals and 1 × 107 as the maximum
number of energy evaluations. All other docking parame-
ters remained at their default settings. The resulting docked
orientations within a root mean square deviation (RMSD)
of 0.5 Å were clustered together. The lowest energy clus-
ter for each compound, returned by AutoDock, was used for
FIGURE 2 | Views of the simulation system, (A) after minimization and (B) after the MDS. Notice that SV2A rearranges within the lipid bilayer.
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FIGURE 3 | Root mean square deviation values for (A) the whole
backbone and (B) the backbone of the TM region as a function of time.
The gray bands correspond to the SD and the line within them represents the
average value.
FIGURE 4 | Radius of gyration values for (A) the whole backbone and
(B) the backbone of the TM region as a function of time. The gray bands
correspond to the SD and the line within them represents the average value.
further analysis. The script and ﬁles used were prepared with
AutoDock Tools 1.5.6 and this software was also used to
visualize all the ligand–protein complexes together with VMD
1.9.1 (Humphrey et al., 1996). All the artwork was created
using Gnuplot 4.6, VMD 1.8, Pymol 1.5 and Photoshop CS5
Extended 12.
FIGURE 5 | Number of H-bonds as a function of time, (A) protein
intra-molecular, (B) protein–water and (C) protein–lipid. The gray bands
correspond to the SD and the line within them represents the average value.
Results
SV2A Modeling
After sending the SV2A protein sequence (FASTA format) to
the I-Tasser server, it returned ﬁve possible 3D models with 12
α-helical TM segments, two long loops and a long cytoplas-
mic N-terminus. The C-score was between -2.84 to -3.02, the
TM-score was 0.39 ± 0.13 and the RMSD was 15.4 ± 3.4 Å.
The Ramachandran plot showed ϕ and ψ angles of 94.7–96.2
% in the favored-allowed regions of the SV2A models. In four
of the models, the TM region was invaded importantly by
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the N-terminus. They were discarded for this reason and the
model with an N-terminus separate from the TM region was
selected (model 3; Figure 1). Moreover, the CPHmodels-3.2
and 3D-JIGSAWv3.0 servers were used to build 3D models
of SV2A to conﬁrm reproducibility. Both servers generated a
structure quite similar to the I-Tasser model, predicting 12 TM
regions.
Molecular Dynamics Simulations
The selected SV2A model was inserted into a POPC membrane
and a MDS was performed to obtain a highly reliable 3D struc-
ture. Figure 2 shows the simulation system after structural mini-
mization (Figure 2A) and after 50 ns of MDS (Figure 2B). Notice
the rearrangement of the SV2A protein, which indicates that
conformational changes occur in the extra and intra-membrane
domains, being greatest in loop structure components. The MDS
allowed SV2A to re-accommodate within the membrane region,
producing a more reliable system to perform docking studies of
known ligands.
Figure 3 shows the RMSD values for α-carbons of the whole
backbone (Figure 3A) or α-carbons of the TM backbone helical
domains (Figure 3B). RMSD values typically help to visual-
ize global structural changes to determine protein stability. The
lower RMSD values (0.21 ± 0.04 nm) of the TM helical domains
(Figure 3B), compared to the whole backbone (Figure 3A), indi-
cate strong conformational changes in extra-membrane regions.
The RMSD slope became modest at ∼20 ns and tended to
zero beyond ∼30–35 ns. The RMSD values suggest that the
system reaches equilibrium, as conﬁrmed by the Rg values
(Figure 4).
The Rg of the whole protein backbone did not show a clear
trend throughout the 50 ns trajectory (Figure 4A); it oscillated
around an average value of 3.43 ± 0.02 nm. However, the vari-
ation was much lower when only the backbone atoms of the
TM helical domain were considered (Figure 4B), although the
Rg values for this region tended to increase slightly. This could
be due to the fact that SV2A is an integral membrane pro-
tein with fairly stable TM domains and ﬂexible extra-membrane
portions.
The number of intra-molecular (Figure 5A), protein–water
(Figure 5B) and protein–lipid (Figure 5C) H-bonds was deter-
mined as a function of time, based on geometrical criteria
(donor–acceptor distance cutoﬀ <3.5 Å and donor-H-acceptor
angle <30◦). Changes in inter-helical hydrogen bonding are
associated with the conformational dynamics of membrane pro-
teins (Bondar and White, 2012). Most H-bonds corresponded
to protein–solvent interactions, while only a few were formed
between SV2A and the lipid heads. There was signiﬁcant
variation in the number of intra-molecular H-bonds that may
correspond to a conformational change; however, this number
reached an equilibrium value during the last part of the trajec-
tory.
To obtain more structural details about the behavior of the
protein, the RMSF of the α-carbon positions throughout the
whole trajectory were calculated. These values indicated that
the most ﬂexible parts of SV2A were the loops located outside
the membrane; i.e., the N-terminus, the large cytoplasmic loop
between the sixth-seventh TMregions and the large intra-luminal
loop between the seventh-eighth TM domains (residues 476–594;
Figure 6).
On the other hand, protein solvent contacts were studied using
SAS, which is a measure of the protein surface exposed to the
solvent. The total SAS and the contributions of hydrophobic or
hydrophilic groups to the SAS were determined as a function of
time (Figure 7A). No signiﬁcant changes were observed along
the trajectory. The SAS of the protein exposed to water decreased
slightly (Figure 7B), whereas the SAS of the protein exposed to
lipids increased a little (Figure 7C).
Solvent accessible surface area by residues exposed to the
membrane hydrophobic core helps to evidence the localization
of several amino acids. Figure 8 shows the total area exposed
to the membrane by residues. Some residues in the loops, N-
terminus and ATP binding motif interacted with the membrane.
The TMhelical domains can be determined, since the highest SAS
values correspond to residues totally exposed to the membrane
hydrophobic core (Figure 8).
In principal components analysis, the α-carbon matrix of
SV2A shows a positive correlation between atomic motions of the
large extra-vesicular loop andN-terminal segment (Figure 9A). It
revealed that only 2–3 components are relevant for the trajectory.
The projection of the trajectory onto the two principal eigen-
vectors shows a structure that reached equilibrium in the last
portion of the trajectory; illustrated by denser yellow–red regions
(Figure 9B).
The results of the replicate MDS were, in general, in agree-
ment with the data obtained in the ﬁrst MDS (data not shown).
Although details varied, all MDS parameters behaved in a
similar manner. In particular, the TM domains arrived at a
conformational equilibrium; whereas the extra-membrane com-
ponents remained mobile.
Docking Studies
The values for the G of binding between SV2A and the
racetams varied between -5.26 and -8.82 Kcal/mol throughout
the last 16 ns of the MDS trajectory (Table 1). The results
showed the same aﬃnity pattern in all evaluated conformations:
UCB30889 > BRIV > SEL > LEV; which is in agreement with
experimental SV2A binding data (Table 2; Noyer et al., 1995;
Gillard et al., 2003, 2011; Bennett et al., 2007).
Ligand binding in dockings showed a clear preference for the
following residues: T456, S665, W666, D670 and L689. These
residues are within TM domains 7, 10 and 11. According to
the SAS analysis these amino acids show values of zero or very
close, which means that they are totally exposed to the membrane
hydrophilic core (i.e., the pore or channel). Contacts between
SV2A and the racetams were dominated by hydrophobic inter-
actions and H-bonds. Every racetam showed a particular pat-
tern of interactions when bound to SV2A; even if they shared
some residues, the interaction was not the same in all cases.
Figure 10 shows schematic representations of the interactions
between the last SV2A conformer (50 ns) of the MDS and
LEV (Figure 10A), BRIV (Figure 10B), SEL (Figure 10C) or
UCB30889 (Figure 10D).
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Discussion
Trans-membrane proteins are diﬃcult to crystallize; thus com-
putational techniques such as protein folding using homol-
ogy modeling and MDS have been very useful tools to obtain
information about their structural properties. The I-Tasser server
was used to generate a full-length 3D model of SV2A with ade-
quate structural predictions and acceptable quantitative assess-
ments (Zhang and Skolnick, 2004; Zhang, 2008; Nugent and
Jones, 2012). Modeling the extra-membrane loops was much
more challenging than the TM regions, primarily due to sparse
contacts or poor predictions of them; additionally, inherent
loop ﬂexibility imposed extra diﬃculties. Nevertheless, I-Tasser
modeled the N-terminus and the two long loops quite sim-
ilar to the secondary structure predicted by UniProt (2014).
It is clear, however, that more sophisticated strategies will be
required to overcome a number of current limitations in this area
(Nugent and Jones, 2012).
FIGURE 6 | Graphic RMSF representations. (A) RMSF of the atomic positions and (B) representation of protein flexibility as a gradient from low to high
fluctuations.
FIGURE 7 | Evolution of the total, hydrophobic and hydrophilic protein SAS; (A) exposed to water plus lipids, (B) exposed to water or (C) exposed to
lipids as a function of time.
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FIGURE 8 | Solvent accessible surface area by residues exposed to the membrane inner core. The highest values correspond to amino acids totally
exposed to membrane hydrophobic core.
Although the obtained structure was acceptable, it was fur-
ther reﬁned by running a MDS. It showed the time dependent
behavior of SV2A and provided detailed information on its ﬂuc-
tuations and conformational changes. The RMSD results showed
that SV2A reached equilibrium in the last 15 ns of the MDS and
this was in agreement with the Rg values. This was also true for
the number of H-bonds, since they remained constant during the
last part of the MDS. The results showed that the TM domains
reached equilibrium and were likely to be correctly modeled;
whereas the regions outside the membrane still remained mobile
(also shown by the RMSF values). This is a general occurrence for
TM proteins (Nugent and Jones, 2012) and it has been reported
for other proteins, such as Bcl-2 (Ilizaliturri-Flores et al., 2013).
Extra-membrane domains, such as the long intra-luminal
loops and N-terminus of SV2A, have post-translational modiﬁca-
tions and interactions with other molecules, whichmight stabilize
the protein conformation in natural conditions (Schivell et al.,
1996, 2005; Nowack et al., 2010). The lack of post-translational
changes and contacts with other molecules (which were not
modeled due to their added complexity) may contribute to the
extensive loop motion. Moreover, the extra-membrane regions of
SV2A were evocative of intrinsically disordered domains within
other proteins, such as Bcl-2 (Rautureau et al., 2010). All of the
above, plus diﬃculties associated to proteins embedded in the
lipid bilayer, may explain why SV2A has not been crystallized
(Hipolito et al., 2014). The relevance of post-translational mod-
iﬁcations on the conformational stability could be explored in
future works with new, longer MD simulations. It is important
to note that the racetam binding site is not part of the extra-
membrane regions and is within the pore, a region in equilibrium
for at least the last 15 ns of the MDS; thus, our model proves to
be of acceptable quality.
Synaptic vesicle protein 2A underwent amino acids rearrange-
ments, mostly in the loop structure components. Figure 2 and the
SAS analysis showed an increase in the protein portion exposed
to lipids; suggesting that amino acids initially exposed to the
aqueous solvent were moving into the lipid bilayer. It is likely
that they required a more hydrophobic environment or more
favorable interactions with the lipid heads. In principal compo-
nents analysis, the variance–covariance matrix of atomic motions
showed which atoms moved together in a concerted way. It con-
ﬁrmed the conformational change that occurred in the large
extra-vesicular loop and N-terminus, which were the most dif-
ﬁcult regions to model and also the most ﬂexible parts of the
protein. The projection of the trajectory onto the two principal
eigenvectors indicated that the protein experienced serious struc-
tural evolution during the ﬁrst 15 ns of the MDS; however, its
structure reached equilibrium in the last part of the trajectory.
We performed docking studies to explore the recognition pat-
tern of racetams in SV2A. Docking studies can be performed
on protein structures obtained from homology modeling, which
maintains the backbone conformation (Tovchigrechko et al.,
2002). However, the SV2A 3D structure obtained from I-Tasser
was reﬁned by performing a MDS; the advantage was that the
side chain residues were energetically accommodated to their
neighbors, resulting in several diﬀerent conformers. Since the
docking procedure lacks protein ﬂexibility, we used the protein
conformers from the MDS to obtain more reliable data, as has
been published elsewhere (Sixto-Lopez et al., 2014). The MDS
and docking simulations were thus combined, since using only
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TABLE 1 | Free energy of binding and residues involved in the interaction between the racetam derivatives and nine SV2A conformers during the MD
trajectory (corresponding to every 2 ns during the last 16 ns), bold residues interacted most frequently.
SV2Asnapshot Ligand G(Kcal/mol) Residues
34 ns LEV −5.88 G452, V453, F455, T456, L628, A664, S665, W666, A668, L669, D670, L689, C693
BRIV −6.58 I273, V453, T456, Y461, Y462, A664, S665, W666, N667, A668, L669, D670, F686, L689, N690, C693
SEL −6.06 G452, V453, F455, T456, Y462, L628, A664, S665, W666, L669, D670, F686, L689, N690, C693
UCB30889 −8.72 D179, I273, M449, M450, G452, V453, F455, T456, Y461, Y462, L628, A664, S665, W666, L669, D670,
L689, N690, C693
36 ns LEV −5.49 I273, V453, T456, Y461, Y462, S665, W666, N667, D670, F686, L689, N690, C693, K694
BRIV −6.28 D179, V183, I273, W300, T456, Y461, Y462, S665, W666, N667, D670, F686, L689, N690, C693, K694,
L695
SEL −5.83 I273, G452, V453, F455, T456, Y461, Y462, A664, S665, W666, N667, L669, D670, F686, L689, N690,
C693, K694
UCB30889 −8.8 I273, G452, V453, T456, Y461, Y462, L628, A664, S665, W666, A668, L669, D670, F686, L689, N690,
C693, K694
38 ns LEV −5.26 M449, G452, V453, F455, T456, F459, L628, S632, A664, S665, W666, A668, L669, D670, L689
BRIV −6.16 D179, I273, W300, T456, Y461, Y462, A664, S665, W666, D670, F686, L689, N690, C693
SEL −5.5 V183, G205, G208, L209, Y212, T456, M457, S458, S460, Y461, Y462, G463, A697, I701
UCB30889 −8.36 V183, V186, K204, G205, G208, L209, Y212, T456, M457, S460, Y461, Y462, V466, A697, I701
40 ns LEV −5.42 D179, V183, I273, W300, T456, Y461, Y462, S665, W666, F686, N690, C693, K694
BRIV −6.4 D179, I273, W300, Y461, Y462, S665, W666, D670, F686, L689, N690, K694, C693
SEL −5.9 D179, V183, I273, W300, Y461,Y462, S665, W666, D670, F686, L689, N690, C693, K694
UCB30889 −8.25 I273, G452, V453, F455, T456, F459, Y461, Y462, A664, S665, W666, L669, D670, F686, L689, N690,
C693, K694
42 ns LEV −5.67 G452, V453, F455, T456, L628, A664, S665, W666, N667, A668, L669, D670, V671, L689
BRIV −6.25 G452, F455, V453, T456, Y462, A664, S665, W666, L669, D670, F686, L689, N690, C693
SEL −5.81 G452, V453, F455, T456, Y461, Y462, L628, A664, S665, W666, A668, L669, D670, F686, L689, N690, C693
UCB30889 −8.49 I273, G452, V453, F455, T456, Y461, Y462, L628, A664, S665, W666, A668, L669, D670, F686, L689, N690,
C693
44 ns LEV −5.67 L176, D179, V183, Y212, I273, F277, W300, Y461, Y462, S665, W666, N690, K694
BRIV −6.91 L176, D179, V183, Y212, I273, F277, W300, Y461, Y462, S665, W666, N667, D670, F686, N690, K694
SEL −6.43 L176, D179, V183, Y212, I273, F277, W300, Y461, Y462, S665, W666, N667, D670, N690, K694
UCB30889 −7.82 L176, D179, V183, Y212, I273, F277, W300, V453, T456, Y461, Y462, S665, W666, L669, D670, F686,
L689, N690, C693, K694
46 ns LEV −5.95 M449, M450, G452, V453, F455, T456, L628, A664, S665, A668, L669, D670, L689, C693
BRIV −7.01 M449, M450, G452, V453, F455, T456, F459, L628, A664, S665, A668, L669, D670, L689, C693
SEL −6.88 M449, M450, G452, V453, F455, T456, F459, L628, A664, S665, A668, L669, D670, L689, C693
UCB30889 −8.51 E182, V183, V186, K204, G205, L207, G208, L209, V211, Y212, R262, Y462, G463, V466
48 ns LEV −5.73 M449, G452, V453, F455, T456, L628, A664, S665, A668, L669, D670, L689, C693
BRIV −6.24 L176, D179, I273, F277, W300, Y461, Y462, S665, W666, D670, F686, N690, K694
SEL −6.04 M449, G452, V453, W454, F455, T456, L628, A664, S665, A668, L669, D670, F686, L689, N690, C693
UCB30889 −8.82 I273, F277, G452, V453, F455, T456, F459, Y461, Y462, A664, S665, W666, L669, D670, F686, L689, N690,
C693, K694
50 ns LEV −5.33 L176, D179, I273, F277, W300, T456, Y461, Y462, S665, W666, D670, F686, N690, K694
BRIV −6.67 F277, G452, V453, F455, T456, Y461, A664, S665, W666, N667, L669, D670, F686, L689, N690, C693
SEL −6.29 F277, G452, V453, F455, T456, Y461, S665, W666, N667, L669, D670, F686, L689, N690, C693
UCB30889 −8.33 I273, F277, G452, V453, F455, T456, Y461, Y462, A664, S665, W666, L669, D670, F686, L689, N690,
C693, K694
one conformation may omit several structural properties and
result in non-biological dockings (Ramirez-Duran et al., 2013).
Our docking studies suggested a consensus binding site for rac-
etam ligands within SV2A constituted by ﬁve residues: T456,
S665, W666, D670 and L689. Tryptophan 666 directly engages
the racetams, mostly by electrostatic interactions. The SV2A pro-
tein with a mutated W666 did not restore synaptic depression
in neurons lacking SV2A and SV2B; showing that this residue is
vital for SV2A neurotransmitter function (Nowack et al., 2010).
Additionally, binding of UCB30889 to SV2A is altered when this
amino acid is mutated, indicating that it may participate in ligand
recognition (Shi et al., 2011).
The SV2A protein has been proposed to be a transporter
owing to its high degree of homology with other mayor facil-
itator super-family (MFS) carriers (Bajjalieh et al., 1992; Feany
et al., 1992; Gingrich et al., 1992) and its compact funnel-shaped
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FIGURE 9 | PCA analysis. (A) Variance–covariance matrix of the SV2A
α-carbon atoms for the 50 ns of the MDS. (B) Projection of the 50 ns
trajectory onto the two principal eigenvectors obtained from the
diagonalization of variance–covariance matrix; time along the trajectory is
represented by a denser gradient.
structure with a visible indentation in the center indicative of a
pore opening (Lynch et al., 2008). Tryptophan 666 is conserved
in all SV2 isoforms and is homologous to a tryptophan in the 10th
TM domain of MFS transporters which is vital for their activ-
ity (Nowack et al., 2010; Shi et al., 2011). Thus, it may provide
the necessary hydrophobic milieu for transport of an endogenous
substrate or LEV, in addition to its involvement in racetam bind-
ing. Residues Y461 and Y462 also frequently interacted with the
racetams (Table 1); both are homologous to functional amino
acids of MFS transporters (Shi et al., 2011). Additionally, Y461
is homologous to a residue important for chloride carrier activity
(Bostick and Berkowitz, 2004).
It has been shown that 14 TM residues alter binding of UCB-
30889 to SV2A when mutated (Shi et al., 2011). The present
results coincide in the importance of W666 for ligand binding.
The other four residues reported here were not mutated in the
previous study. Y462 was also repeatedly found in this study;
TABLE 2 | Mean G of binding during the MD trajectory and experimental
SV2A binding data (see text for references).
Ligand G (kcal/mol, Mean ± SD) Experimental SV2A pKd
Levetiracetam −5.60 ± 0.24 6.1
Brivaracetam −6.50 ± 0.31 7.2
Seletracetam −6.08 ± 0.41 7.1
UCB30889 −8.46 ± 0.32 7.6
however, the 12 other amino acids described in the prior work
were not regularly detected. These discrepancies may be due to
the following: (1) SV2A was transiently expressed in COS-7 cells
which are far removed from neurons, (2) the true functionality
of SV2A mutants was unclear since they were not likely to exit
the endoplasmic reticulum or Golgi (Nowack et al., 2010), (3)
the residues that altered binding to UCB-30889 were not nec-
essarily part of the ligand pocket; they may aﬀect other aspects,
such as changing the native conformation or stability of the pro-
tein. This, in turn, may change important aspects, such racetam
access, retention or expulsion. These phenomena are not mod-
eled by docking studies, which only predict ligand aﬃnity for a
region of the protein. AMDS of SV2A together with the racetams
would be useful to further reﬁne the interactions of SV2A and its
racetam ligands.
The 3D model generated by I-Tasser and the structure
obtained after the MDS show that the TM portions of SV2A may
be accessed by the racetams. As previously suggested, LEV and
related racetams likely enter into recycling vesicles, gain access
to SV2A from its luminal side and bind in its TM segments
(Meehan et al., 2011, 2012; Mendoza-Torreblanca et al., 2013).
Once bound to SV2A, racetams inhibit its function; reducing the
ready releasable vesicular pool and synaptic transmission, pref-
erentially during long high frequency activity (Xu and Bajjalieh,
2001).
Modeling of the complete SV2A protein was challenging due
to its large size (742 amino acids), its long N-terminus and
its two long loops. However, a valid 3D model was obtained
and the 50 ns of MDS were enough to reach structural equi-
librium of the protein. The racetam binding site in SV2A was
identiﬁed by docking studies employing diﬀerent SV2A snap-
shots to explore the protein motion involved in ligand recog-
nition; it showed that ﬁve residues participate in ligand recog-
nition. Given the biological and pharmacological importance
of SV2A, knowing its conformation is essential to direct fur-
ther experimental work in order to elucidate its function and
attempt the discovery of new ligands. Additionally, knowing
the racetam binding site within SV2A should facilitate syn-
thesizing suitable radio-ligands for PET studies with a high
aﬃnity and speciﬁcity. This, in turn, should allow the in vivo
evaluation of treatment response and possibly disease progres-
sion.
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FIGURE 10 | Putative racetam binding site within the last SV2A conformer of the MDS. 3D models and schematic representations of the interactions
between SV2A and (A) LEV, (B) BRIV, (C) SEL or (D) UCB30889 are shown. Hydrophobic interactions and H-bonds participate importantly in ligand recognition
within the binding site (amino acids in circles).
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